Diagnosing Common Benign Skin Tumors

Joy Shen-Wagner, MD
Joel Amidon, MD
Stephen Carek, MD

American Family Physician. 2024;110(4):353-361.

Author disclosure: No relevant financial relationships.

This clinical content conforms to AAFP criteria for CME.

Patients commonly present to family physicians with skin findings, and distinguishing common benign skin tumors from potentially malignant tumors is important. Benign skin tumors can often be diagnosed by their history, distribution, and characteristic morphology. A biopsy or excision is indicated if there is diagnostic uncertainty or the lesion undergoes uncharacteristic or rapid change. A keratoacanthoma is a dome-shaped nodule with a central crater and can be difficult to distinguish from squamous cell carcinomas even with dermoscopy. Pilar cysts are typically benign, but rapidly growing types could have malignant qualities. Dermoid cysts, depending on their location, can have intracranial extension if untreated. Although dermatofibromas and seborrheic keratoses are benign, atypical presentations must be differentiated from melanomas. Sebaceous hyperplasia can mimic early basal cell carcinoma. Treatment options for cherry angiomas, acrochordons, slow-growing pilar cysts, and dermatofibromas should be individualized to skin type, lesion characteristics, and the patient's cosmetic preference. Generally, excision is the treatment of choice for keratoacanthomas, rapidly proliferating pilar cysts, and dermoid cysts. Cherry angiomas are treated with laser therapy and sebaceous hyperplasia with electrodesiccation. Common treatments for acrochordons and seborrheic keratoses are shave excision and cryotherapy. Pyogenic granulomas sometimes self-involute but bleed easily and often recur at the original site. They generally respond to shave excision and electrodesiccation. In patients with darker skin, treatment with cryotherapy and laser therapy should include discussions about hypopigmentation risk.

JOY SHEN-WAGNER, MD, FAAFP, is an associate professor in the Department of Family Medicine at Prisma Health and the University of South Carolina School of Medicine, Greenville.

JOEL AMIDON, MD, is the associate program director of and an assistant professor in the Department of Family Medicine at Prisma Health and the University of South Carolina School of Medicine.

STEPHEN CAREK, MD, is the program director of and an associate professor in the Department of Family Medicine at Prisma Health and the University of South Carolina School of Medicine.

Address correspondence to Joy Shen-Wagner, MD, at joy.shen-wagner@prismahealth.org.

Author disclosure: No relevant financial relationships.

  1. 1.Lowell BA, et al. Dermatology in primary care. J Am Acad Dermatol. 2001;45(2):250-255.
  2. 2.Higgins JC, et al. Diagnosing common benign skin tumors. Am Fam Physician. 2015;92(7):601-607.
  3. 3.Juckett G, et al. Management of keloids and hypertrophic scars. Am Fam Physician. 2009;80(3):253-260.
  4. 4.Ren WW, Wu L, Wang Q, et al. The value of ultrasound for differentiating trichilemmal cysts from epidermoid cysts. J Ultrasound Med. 2023;42(9):1941-1950.
  5. 5.Golden BA, Jaskolka MS, Ruiz RL. Craniofacial and orbital dermoids in children. Oral Maxillofac Surg Clin North Am. 2012;24(3):417-425.
  6. 6.Reissis D, Pfaff MJ, Patel A, et al. Craniofacial dermoid cysts. Yale J Biol Med. 2014;87(3):349-357.
  7. 7.American Academy of Dermatology Association. Warts: overview. https://www.aad.org/public/diseases/a-z/warts-overview
  8. 8.Banik R, Lubach D. Skin tags. Dermatologica. 1987;174(4):180-183.
  9. 9.Belgam Syed SY, Lipoff JB, Chatterjee K. Acrochordon. StatPearls. August 8, 2023. Accessed August 8, 2023. https://www.ncbi.nlm.nih.gov/books/NBK448169/
  10. 10.Clebak KT, Mendez-Miller M, Croad J. Cutaneous cryosurgery for common skin conditions. Am Fam Physician. 2020;101(7):399-406.
  11. 11.Liu A, Taylor MB, Sotoodian B. Treatment of sebaceous hyperplasia by laser modalities. J Drugs Dermatol. 2020;19(5):547-552.
  12. 12.Yu C, Shahsavari M, Stevens G, et al. Isotretinoin as monotherapy for sebaceous hyperplasia. J Drugs Dermatol. 2010;9(6):699-701.
  13. 13.Marghoob AA, Usatine RP, Jaimes N. Dermoscopy for the family physician. Am Fam Physician. 2013;88(7):441-450.
  14. 14.Fitzpatrick's Color Atlas and Synopsis of Clinical Dermatology. 9th ed. McGraw-Hill Education; 2023.
  15. 15.Dermnet. Sebaceous hyperplasia. Updated June 2014. Accessed June 2023. https://dermnetnz.org/topics/sebaceous-hyperplasia
  16. 16.Sullivan JJ. Keratoacanthoma: the Australian experience. Australas J Dermatol. 1997;38(suppl 1):S36-S39.
  17. 17.Kwiek B, Schwartz RA. Keratoacanthoma (KA): an update and review. J Am Acad Dermatol. 2016;74(6):1220-1233.
  18. 18.Tran DC, Li S, Henry S, et al. An 18-year retrospective study on the outcomes of keratoacanthomas with different treatment modalities at a single academic centre. Br J Dermatol. 2017;177(6):1749-1751.
  19. 19.Lee J, Sinno H, Tahiri Y, et al. Treatment options for cutaneous pyogenic granulomas. J Plast Reconstr Aesthet Surg. 2011;64(9):1216-1220.
  20. 20.Plachouri KM, Georgiou S. Therapeutic approaches to pyogenic granuloma: an updated review. Int J Dermatol. 2019;58(6):642-648.
  21. 21.Dany M. Beta-blockers for pyogenic granuloma. J Drugs Dermatol. 2019;18(10):1006-1010.
  22. 22.Zaballos P, Puig S, Llambrich A, et al. Dermoscopy of dermatofibromas. Arch Dermatol. 2008;144(1):75-83.
  23. 23.Beatrous SV, et al. Associated conditions in patients with multiple dermatofibromas. Dermatol Online J. 2017;23(9):13030/qt8zv852d8.
  24. 24.Ahlgrimm-Siess V, Cao T, Oliviero M, et al. Seborrheic keratosis. J Am Acad Dermatol. 2013;69(1):120-126.
  25. 25.Baumann LS, Blauvelt A, Draelos ZD, et al. Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses. J Am Acad Dermatol. 2018;79(5):869-877.
  26. 26.Bernett CN, Davidson CL, Schmieder GJ. Leser Trélat sign. StatPearls. Updated February 2024. Accessed March 1, 2024. https://www.ncbi.nlm.nih.gov/books/NBK470554/
  27. 27.Wollina U. Recent advances in managing and understanding seborrheic keratosis. F1000Res. 2019;8:F1000.
  28. 28.Luba MC, Bangs SA, Mohler AM, et al. Common benign skin tumors. Am Fam Physician. 2003;67(4):729-738.
  29. 29.Buslach N, Foulad DP, Saedi N, et al. Treatment modalities for cherry angiomas: a systematic review. Dermatol Surg. 2020;46(12):1691-1697.
  30. 30.Betz-Stablein B, et al. Anatomic distribution of cherry angiomas in the general population. Dermatology. 2022;238(1):18-26.
  31. 31.Hörer S, et al. A monoallelic two-hit mechanism in plcd1 explains the genetic pathogenesis of hereditary trichilemmal cyst formation. J Invest Dermatol. 2019;139(10):2154-2163.e5.
  32. 32.Lee DY, et al. A malignant proliferating trichilemmal cyst arising on the elbow of a man. Medicine (Baltimore). 2023;102(25):e34035.
  33. 33.Hoang VT, Trinh CT, Nguyen CH, et al. Overview of epidermoid cyst. Eur J Radiol Open. 2019;6:291-301.
  34. 34.Zuber TJ. Minimal excision technique for epidermoid (sebaceous) cysts. Am Fam Physician. 2002;65(7):1409-1412.
  35. 35.Swygert KE, Parrish CA, Cashman RE, et al. Melanoma in situ involving an epidermal inclusion (infundibular) cyst. Am J Dermatopathol. 2007;29(6):564-565.
  36. 36.Pryor SG, Lewis JE, Weaver AL, et al. Pediatric dermoid cysts of the head and neck. Otolaryngol Head Neck Surg. 2005;132(6):938-942.

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.